Pampa Energía SANYSE: PAM

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.

Pampa (PAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Does Pampa Energia (PAM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.

Pampa Energia (PAM) makes a strong case for investment, given its growth prospects, strong ROE, debt management and focus on clean power generation.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

At Zacks, we prioritize the reliable Zacks Rank system, which looks at earnings estimates and revisions to identify top-performing stocks. However, we also keep a close eye on current value, growth, and momentum trends to highlight strong investment opportunities.

Pampa Energía S.A. (NYSE:PAM ) Q4 2023 Earnings Conference Call March 7, 2024 10:00 AM ET Company Participants Raquel Cardasz - IR Lida Wang - Head, IR & Sustainability Gustavo Mariani - CEO Nicolás Mindlin - CFO Horacio Turri - Head, Exploration & Production Conference Call Participants Raquel Cardasz Good morning everyone and thank you for waiting.